WASHINGTON — In a presentation at the Rising Leaders Conference on Healthcare Policy, Kate Rawson discussed what to expect with the Direct-to-Consumer Price Disclosure Rule proposed by CMS.
Proposed as a way to increase transparency on drug pricing, the Direct-to-Consumer Price Disclosure Rule allows HHS to “call on FDA to evaluate the inclusion of list prices in direct-to-consumer advertising,” Rawson, who is a senior editor at Prevision Policy LLC, said.
Although the legal basis and price impact of the rule are unknown, according to Rawson, it has prompted the Pharmaceutical

Source link